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ScienceDirectA number of appetite-regulating gut hormones alter behaviors
linked to reward, anxiety/mood, memory and cognitive
function, although for some of these (notably GLP-1 and CCK)
the endogenous signal may be CNS-derived. From a
physiological perspective it seems likely that these hormones,
whose secretion is altered by nutritional status and by bariatric
weight loss surgery, orchestrate neurobiological effects that
are integrated and linked to feeding/metabolic control.
Consistent with a role in hunger and meal initiation, ghrelin
increases motivated behavior for food and, when food is not
readily available, decreases behaviors in anxiety tests that
would otherwise hinder the animal from finding food. Of the
many anorexigenic signals, GLP-1 and PYY have been linked to
a suppressed reward function and CCK (and possibly GLP-1) to
increased anxiety-like behavior.
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Introduction
Interest in enteroendocrine gut–brain signaling has esca-
lated in recent years as obesity researchers try to figure out
why certain bariatric procedures that involve surgical
rearrangement of the stomach and upper gut cause weight
loss and improve dietary choice [1,2]. The enteroendo-
crine cells of the gut produce a large number of appetite-
regulating peptides, many of which have altered secretion
in association with bariatric surgery [3] and weight loss
[4]. Indeed, these hormones impact not only on brain
centers regulating appetite and metabolic control, but
also on pathways orchestrating behaviors linked to
 
Open access under CC BY-NC-ND license.www.sciencedirect.com reward, mood, anxiety, stress and memory, among others.
Interestingly, such behaviors may also be influenced by
the composition of the gut microbiota, communicating
with the CNS possibly through neural, endocrine and
immune pathways [5]. The consequence of altering the
gut endocrine and microbiota milieu on behavior is a new
and emerging field. Here we focus, in particular, on
appetite-regulating gut hormones, including those linked
to the successful weight loss outcome of bariatric surgery,
and their effect on relevant behaviors important for
appetite control, reward and mood.
In normal physiology, the secretion of appetite-regulating
gut hormones changes according to metabolic need;
whereas the orexigenic hormone ghrelin is secreted by
the A-like cells in the stomach preprandially and in
association with hunger [6], the anorexigenic peptides
glucagon-like peptide 1 (GLP-1) and Peptide YY (PYY)
are cosecreted from the L-cells of the small intestine,
shown both in cultured cells [7] and in vivo after a meal
[8,9]. GLP-1 may even be secreted before a meal, as part
of the cephalic response to food anticipation [10,11].
Cholecystokinin (CCK), another anorexigenic gut pep-
tide produced by the I cells, appears to operate as a satiety
hormone [12] and its release is triggered by the presence
of food in the gut, especially in association with meals rich
in fat and protein [13]. Both GLP-1 and CCK have a
relatively short half-life in the circulation. As both are
produced in discrete cell groups within the brain [14,15],
it would be difficult to ascertain whether behavioral
effects observed following exogenous delivery of these
peptides mimic an afferent gut–brain signal or whether it
is CNS-derived.
An overarching hypothesis to be discussed here is that
many of the behavioral effects of enteroendocrine hor-
mones are likely to be directly or indirectly linked to
appetite and metabolic control. Thus, for example, in
established behavioral tests of reward, anxiety, depres-
sion and memory, hungry animals are likely to perform
differently to fed animals reflecting, at least in part, an
altered enteroendocrine gut–brain axis; the hungry
animal will be more motivated to find food and will be
more willing to overcome an aversive environment in
order to get it.
Before examining the impact of gut hormones on beha-
vior, it is important to discuss complexities and limitations
of such investigations. Firstly, as already mentioned,
some ‘gut’ peptides are actually gut/brain peptides and
so a change in an observed behavior may not be controlled
by the enteroendocrine gut but the brain peptide sourceCurrent Opinion in Pharmacology 2013, 13:977–982
978 Endocrine and metabolic diseasesinstead. A prominent example here is GLP-1, whose
central effects may be driven from cell groups in the
brainstem [14]. Secondly, brain sensitivity to the hor-
mone may change in relation to different (patho)phy-
siological states, especially those that involve changes
in energy balance, both short term (e.g. fasting) and
chronic (e.g. obesity). At least for ghrelin, the brain may
show increased sensitivity to this hormone in fasting
[16] and resistance to it in obesity [17]. Thirdly, the
constructs measured in behavioral tests often involve
changes in locomotor activity (e.g. searching for food,
moving into an open field) and also involve memory
processing (e.g. that a certain environment or task is
associated with a beneficial or aversive outcome); if
behavioral outcomes change as the result of the admin-
istration of a hormone, it can be difficult to exclude
effects of locomotor activity and memory per se. Finally,
behavioral testing must carefully control for stress,
which can alter the outcome of almost all behavioral
tests and, in some cases, also can change enteroendo-
crine gut hormone levels.
Appetitive behavior
‘Appetitive behavior’ is an umbrella term that essentially
describes all behaviors that precede (and ultimately lead
to) food consumption. These behaviors change accordingFigure 1
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(motivational) value of food. Thus, as a test of food
reward, hungry animals will show increased preference
for an environment previously paired to a food reward,
even when the food is no longer available — the so-called
‘condition place preference’ (CPP) test. There are indications
that enteroendocrine cells of the gut and/or their brain
signaling systems suppress CPP for food, exemplified by
studies that utilize anorexigenic agents such as the long
acting GLP-1 receptor agonist, Exendin 4 [18] and also
ghrelin receptor (GHS-R1A) antagonists [19,20]. Further
evidence that gut hormones regulate food reward is
suggested by studies exploring the incentive motivational
value of food rewards — the so-called ‘operant responding’
paradigm, in which rats trained to press a lever for food
will work increasingly hard to obtain a food reward. In this
test, ghrelin has been shown to increase motivation for
sucrose in fully fed rats, when delivered peripherally,
centrally [21] or directly into the ventral tegmental area
(VTA) [22], a key brain area involved in reward-seeking
behaviors [23] (Figure 1a). Conversely, a ghrelin antagon-
ist was shown to suppress motivated behavior for a sucrose
reward, even in fasted animals that have high levels of
endogenous ghrelin [21,22,24]. In another study, using a
high-fat diet as a reinforcer, suppressed ghrelin signaling
in mice (both pharmacologically and in genetic knockoutARD
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and operant responding paradigms [20]. The effects of
ghrelin on food reward behavior involves the midbrain
dopamine system [25–27] that has an established role in
incentive motivation (i.e. wanting). Notably, midbrain
dopamine might not be essential for ghrelin-induced food
consumption that does not require a significant effort,
indicating that the neurocircuitry controlling effort-based
food seeking may be divergent from that controlling
simply intake [28]. Ghrelin does not appear to directly
target food palatability [29] that involves hedonic proces-
sing (i.e. liking). Thus, ghrelin appears to play a role in
over-eating beyond metabolic need, especially promoting
behaviors that lead to the consumption of palatable/
rewarding foods that are calorie dense [25]. The central
ghrelin signalling system has also been linked to a num-
ber of other appetitive behaviours that include, for
example, food anticipatory activity in rodents [30,31]
and food hoarding and foraging behaviours in Siberian
hamsters [32].
Not all ‘postprandial’ enteroendocrine hormones have
been shown to have a clear role to suppress food-motiv-
ated behavior in rodents. This is perhaps not surprising as,
from an evolutionary perspective, it may not be beneficial
to limit excessive food intake, especially palatable foods
of diverse nutritional value, when food is available in
order to stock up energy reserves for future famine. Brain
centers involved in homeostatic and hedonic [33] evalu-
ation of food have been shown to have altered activity
after PYY delivery to fasting human subjects [34].
Although both PYY and NPY bind to the NPY-Y1 re-
ceptor, to the best of our knowledge, only NPY has been
shown to impact on food motivated behavior in rodents
[35]. Likewise, central CCK signaling has not yet been
shown to alter food reward behavior, although there is
considerable literature linking CCK signaling with
chemical drug reward [36] and anxiety [37]. The central
GLP-1 signaling system stands out as the only anorexi-
genic ‘gut’ hormone with a clear role to suppress food
reward behavior. Thus, peripheral administration of
Exendin 4 suppresses CPP for chocolate pellets and also
operant responding for sucrose pellets, involving sig-
naling via central GLP-1 receptors [18]. Unlike ghrelin,
GLP-1 has also been linked to reduced food palatability
[38]. The hindbrain GLP-1 producing neurons can
directly supply GLP-1 into the mesolimbic reward areas,
again making it difficult to distinguish whether the gut or
the brain is the relevant endogenous source of the agonist
[39–41].
Reward behavior for chemical drugs of abuse
Chemical substances of abuse essentially hijack the
brain’s natural reward system. Given that brain areas
involved in reward processing express receptors for gut
peptides such as ghrelin [42], PYY [43], CCK [44], and
GLP-1 [45], it is perhaps not surprising that some gutwww.sciencedirect.com hormones alter reward behavior for chemical substances
of abuse, and not only natural reward such as food.
Indeed, food reward-regulating gut hormones alter con-
sumption of (and reward behavior for) artificial reward
reinforcers such as alcohol [46,47] and cocaine [48,49]. In
a free-choice (alcohol/water) limited access paradigm,
alcohol intake has been shown to be increased by per-
ipheral, intracerebroventricular (ICV) or intra-VTA deliv-
ery of ghrelin [47] and suppressed by GLP-1 or GLP-1
agonists delivered peripherally [46,50] or intra-VTA [46].
Indeed, in these studies, CPP for alcohol as well as other
reward parameters was shown to be suppressed by per-
ipheral administration of ghrelin antagonists and GLP-1
agonists. Both ghrelin and GLP-1 have been investigated
for their potential involvement in chemical drug reward
and associated behaviors in rodents. In accordance with
the results described above for food reward, ghrelin seems
to increase while GLP-1 may decrease cocaine and
amphetamine-induced behaviors [48,49,51].
Emotional reactivity and mood
When describing behavioral studies exploring the effects
of enteroendocrine hormones on emotional reactivity, it is
important to realize that the classic tests used were
developed to assess anxiolytic and anti-depressant drugs.
If, for example, a rat spends more time in the open arm in
the elevated plus maze, the rat is considered less anxious.
However, if hungry, this behavior could reflect increased
exploratory behavior to find food. Thus, the term
‘anxiety-like’ has been coined to describe the behavioral
outcome of such tests. In different studies, ghrelin has
been suggested to increase anxiety-like behavior in rats
[52–55], including in one chronic study in which ghrelin
was delivered to the brain [56] and, paradoxically, to
reduce the depressive and anxiogenic effects of acute
stress in mice [57]. In one recent study, we sought to gain
clarification of this discrepancy by directing ghrelin injec-
tion to the amygdala, a key brain area involved in
emotional reactivity and, in particular, to a part of the
amygdala where GHS-R1A was most abundant. We found
that intra-amygdala ghrelin administration decreased
anxiety-like behavior (in the elevated plus maze and
open field tests) but only in rats not allowed to feed
during the initial 1 hour period after the ghrelin injection
[58] (Figure 1b). In line with the idea that anxiety-like
behavior and exploration are regulated in an opposite
manner by ghrelin, we recently showed that rats not given
access to food after ghrelin injection increase their
novelty-seeking behavior [59]. Thus, when food is not
available, the hunger signal provided by ghrelin may
suppress anxiety-like behaviors in order to help the
animal find food. While the role of ghrelin in anxiety-
like behavior remains somewhat controversial, a wealth of
evidence links CCK to anxiety behavior (see [60,61] for
review). Both human and rodent studies clearly indicate
that elevated CCK is associated with increased anxiety-
like behavior. This effect is demonstrated in a variety ofCurrent Opinion in Pharmacology 2013, 13:977–982
980 Endocrine and metabolic diseasesanxiety models, including those that are exploration-
based as well as potentiated startle models. The site of
effect seems to be central, with the basolateral amygdala
and, to some degree, hippocampus and cortical areas
being direct targets for the anxiety-inducing effects of
CCK [62–64].
The contribution of GLP-1 and its receptors to anxiety
behaviors is less clear and seemingly contradictory results
have been obtained in human versus rodent studies. In
rodents central GLP-1 injection reduced the amount of
time exploring the open arm of the elevated plus maze, an
effect mimicked by a direct intra-amygdala GLP-1
administration [65]. The available human data, however,
suggest the exact opposite, a role for GLP-1 in reducing
anxiety. Short-term infusion of GLP-1 did not result in
anxiety in healthy subjects [66]. Furthermore, in patients
with type 2 diabetes, administration of a GLP-1 based
therapy for 6 months resulted in a reduction in anxiety
and depression scores [67].
Ghrelin, GLP-1 and CCK have also been investigated for
their role in panic attacks. While CCK leads to a reliable
induction of panic attacks, even in healthy humans, GLP-
1 did not produce any changes in both healthy subjects
and those diagnosed with panic disorder [66]. For ghrelin,
a polymorphism in the preproghrelin gene was shown to
be associated with panic disorder by one study [68] but
another reports no association [69].
Conclusions
In summary, appetite regulating enteroendocrine gut
peptides impact on a number of behaviors, many of which
are likely directly or indirectly linked to feeding control.
From a therapeutic perspective, gut hormones and drugs
that interfere with their brain signaling mechanisms, may
have potential for development in diseases areas other
than obesity and eating disorders, that include addictive
behavior and anxiety disorders.
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